Stem Cell Therapy advancements, page-357

Again, not strictly related (but OCC cite them in their investor presentations) in stem cells, but another Aussie tissue regeneration involving autologous cellular therapy progressing in the US:

https://finance.yahoo.com/news/avita-medical-submits-fda-pma-141500845.html

Extending to level I and II trauma centres in the US - I see a similar eventual network of what are called ambulatory centers (we'd call them out patient medical centres) happening in the case of Ortho ATI, if the company is successful in its plans.

Many of you will know that in February 2022, the FDA approved the an aspect of its autologous cell harvesting as part of this therapy. Again, the market appears to miss these small, but important changes in the backdrop for OCC in its ease of getting the FDA to approve Ortho ATI. This yet another significant acceptance of autologous cellular therapies (by an Aussie company no less) by the FDA, that was frankly far more of an unknown hurdle pre-COVID.